Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 4/20 | 0.46 |
| ▸ | NTMT1 | Q9BV86 | 2/20 | 0.42 |
| ▸ | APLNR | P35414 | 7/20 | 0.42 |
| ▸ | F2 | P00734 | 2/20 | 0.39 |
| ▸ | REN | P00797 | 3/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29765149 | 0.91 | ACE (0.40) | ACENTMT1APLNR | |
| SCHEMBL29816167 | 0.89 | ITGB3 (0.42) | ACENTMT1APLNRF2REN | |
| SCHEMBL30697833 | 0.89 | ITGB3 (0.42) | ACENTMT1APLNRF2REN | |
| SCHEMBL31158134 | 0.88 | ACE (0.38) | ACENTMT1APLNRREN | |
| SCHEMBL29588517 | 0.86 | ACE (0.52) | ACEREN | |
| SCHEMBL29580010 | 0.86 | REN (0.49) | APLNRREN | |
| SCHEMBL29580260 | 0.86 | REN (0.49) | APLNRREN | |
| SCHEMBL29411133 | 0.85 | ACE (0.40) | ACEF2REN | |
| SCHEMBL29411115 | 0.85 | ACE (0.49) | ACENTMT1APLNRF2 | |
| SCHEMBL29411123 | 0.85 | MEN1 (0.49) | ACEREN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260115261-A1 | COLLAGEN PEPTIDE-BASED MEDICAMENT COMPOSITIONS AND USES THEREOF | SUSTAIN HOLDINGS LLC (US) | 2026-04-30 | — | — | US | disclosed |
| US-12551525-B2 | Collagen peptide-based medicament compositions and devices and methods of production and use thereof | SUSTAIN HOLDINGS, LLC (US) | 2026-02-17 | — | — | US | disclosed |
| US-12419936-B2 | Collagen peptide-based medicament compositions and devices and methods of production and use thereof | SUSTAIN HOLDINGS, LLC (US) | 2025-09-23 | — | — | US | disclosed |
| US-20250268974-A1 | COLLAGEN PEPTIDE-BASED MEDICAMENT COMPOSITIONS AND DEVICES AND METHODS OF PRODUCTION AND USE THEREOF | SUSTAIN HOLDINGS, LLC | 2025-08-28 | — | — | US | disclosed |
| US-20250213641-A1 | COLLAGEN PEPTIDE-BASED MEDICAMENT COMPOSITIONS AND DEVICES AND METHODS OF PRODUCTION AND USE THEREOF | SUSTAIN HOLDINGS, LLC | 2025-07-03 | — | — | US | disclosed |
| WO-2025096630-A2 | COLLAGEN PEPTIDE-BASED MEDICAMENT COMPOSITIONS AND USES THEREOF | SUSTAIN HOLDINGS, LLC (US) | 2025-05-08 | — | — | WO | disclosed |
| EP-4543480-A2 | COLLAGEN PEPTIDE-BASED MEDICAMENT COMPOSITIONS AND USES THEREOF | Sustain Holdings, LLC (US) | 2025-04-30 | — | — | EP | disclosed |
| US-12280086-B2 | Collagen peptide-based medicament compositions and devices and methods of production and use thereof | SUSTAIN HOLDINGS, LLC (US) | 2025-04-22 | — | — | US | disclosed |
| CN-119698289-A | Pharmaceutical composition based on collagen peptide and application thereof | 莎思坦控股有限责任公司 | 2025-03-25 | — | — | CN | disclosed |
| CN-118750585-A | Collagen-based pharmaceutical compositions and devices and methods of manufacture and use thereof | 莎思坦控股有限责任公司 | 2024-10-11 | — | — | CN | disclosed |
| WO-2024006771-A2 | COLLAGEN PEPTIDE-BASED MEDICAMENT COMPOSITIONS AND USES THEREOF | SUSTAIN HOLDINGS, LLC (US) | 2024-01-04 | — | — | WO | disclosed |
| US-20230338458-A1 | COLLAGEN PEPTIDE-BASED MEDICAMENT COMPOSITIONS AND DEVICES AND METHODS OF PRODUCTION AND USE THEREOF | SUSTAIN HOLDINGS, LLC | 2023-10-26 | — | — | US | disclosed |
| US-11684651-B2 | Collagen peptide-based medicament compositions and devices and methods of production and use thereof | SUSTAIN HOLDINGS, LLC (US) | 2023-06-27 | — | — | US | disclosed |
| US-20230141917-A1 | COLLAGEN PEPTIDE-BASED MEDICAMENT COMPOSITIONS AND DEVICES AND METHODS OF PRODUCTION AND USE THEREOF | SUSTAIN HOLDINGS, LLC | 2023-05-11 | — | — | US | disclosed |
| US-20230048200-A1 | COLLAGEN PEPTIDE-BASED MEDICAMENT COMPOSITIONS AND DEVICES AND METHODS OF PRODUCTION AND USE THEREOF | SUSTAIN HOLDINGS, LLC | 2023-02-16 | — | — | US | disclosed |
| US-20220280592-A1 | COLLAGEN PEPTIDE-BASED MEDICAMENT COMPOSITIONS AND DEVICES AND METHODS OF PRODUCTION AND USE THEREOF | SUSTAIN HOLDINGS LLC (US) | 2022-09-08 | — | — | US | disclosed |
| US-11433112-B1 | Collagen peptide-based medicament compositions and devices and methods of production and use thereof | SUSTAIN HOLDINGS, LLC (US) | 2022-09-06 | — | — | US | disclosed |
| US-11426440-B2 | Collagen peptide-based medicament compositions and devices and methods of production and use thereof | SUSTAIN HOLDINGS, LLC (US) | 2022-08-30 | — | — | US | disclosed |
| US-11389513-B2 | Collagen peptide-based medicament compositions and devices and methods of production and use thereof | SUSTAIN HOLDINGS, LLC (US) | 2022-07-19 | — | — | US | disclosed |
| EP-3958889-A2 | COLLAGEN PEPTIDE-BASED MEDICAMENT COMPOSITIONS AND DEVICES AND METHODS OF PRODUCTION AND USE THEREOF | Sustain Holdings, LLC (US) | 2022-03-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260115261-A1 | COLLAGEN PEPTIDE-BASED MEDICAMENT COMPOSITIONS AND USES THEREOF | COL1A1, COL2A1, COL14A1 | ACE 1631/4885NTMT1 2075/4885APLNR 982/4885 |
| US-12551525-B2 | Collagen peptide-based medicament compositions and devices and methods of production and use thereof | COL2A1, COL14A1, COL1A1 | ACE 1610/4885NTMT1 4360/4885APLNR 1803/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.